Gastroenterology and Hepatology
Publication Analysis 1996-2007
by Ralf Neumann, Labtimes 05/2008
|Europe...||... and the World||Most Cited Authors...||... and Papers|
Most Cited Authors - Pictures
Germany dominated European research on the digestive system. The highest citation-per-article ratios, however, were achieved by the Scandinavian nations. “Hottest” topics were hepatitis C and Morbus Crohn.
Gastroenterology and hepatology are clinical disciplines, that’s for sure. This, however, doesn’t necessarily mean that only researchers from clinical institutes are interested in topics to do with the liver, stomach, intestine and pancreas.
Take the liver, for example. It’s not exactly news that the largest organ in the human body is the prime target for hepatitis viruses. Does this mean we would also have to include virology specialists in our publication analysis on gastroenterology and hepatology? A difficult question. However, our response elegantly skirted around the answer. None of the researchers from our earlier analysis on “virus research” (Lab Times 1/2006,pp. 34-36) collected a high enough citation number with their publications 1996-2006 to make it into the top 30 list of Europe’s most-cited researchers in gastroenterology and hepatology (see table p. 42).
Somewhat more success was achieved by human geneticists primarily working on susceptibility genes for diseases of the digestive system. Two of them actually leaped into the Top 30: Gilles Thomas (27th), a specialist geneticist for Morbus Crohn of the Foundation Jean Dausset, Human Polymorphism Study Center in Paris, and Stefan Schreiber (22nd) from the Institute for Clinical Molecular Biology in the University of Kiel, who is working on genetic polymorphisms associated with inflammatory bowel disease and other diseases of the digestive organs.
Three more “cross invaders” from other disciplines remained: Bile salt transport expert Peter Meier (17th), who left his chair of Clinical Pharmacology and Toxicology at the University Hospital Zurich on 1st April 2005 to become Vice-Rector at the University of Basel; biochemist Dietrich Keppler (26th) from the German Cancer Research Center in Heidelberg who studies multidrug resistance proteins in the liver; and German pathologist Manfred Stolte (9th) from Bayreuth hospital who published his most-cited papers about Helicobacter infection and gastric ulcers.
The remaining 25 positions in the Top 30 are occupied by clinicians, working almost exclusively in departments of internal medicine (gastroenterology and hepatology) or departments of surgery.
No wonder, therefore, that clinical researchers dominated even more clearly the particular gastroenterology and hepatology journals which we recruited to analyse the publication performances of individual countries in research on structure, function and diseases of the digestive system (see tables on p. 41).
The basis for this analysis were the 50 journals listed under the gastroenterology and hepatology category of the Journal Citation Report by bibliometric database provider Thomson Scientific. Regrettably, we had to exclude multidisciplinary journals such as Nature and The Lancet from this part of the analysis since Thomson Scientific’s “Web of Science” citation database provides no tools to reliably extract articles pertaining only to gastroenterology and hepatology. Indeed, the most prominent papers in the field might thus have been omitted from this part of the analysis. However, we believe that the countries’ performances in expert journals alone suffice to provide valid indicators for their overall productivity in gastroenterology and hepatology research between 1996 and 2006.
When applying this approach, it surely comes as a little surprise that Germany emerged as Europe’s number one in gastroenterology and hepatology research, particularly since the country’s system of clinical research has constantly been under fire for its presumed inefficiency and lack of quality. Our analysis doesn’t support this view – at least for the gastroenterology and hepatology side of clinical research. Articles in specialist journals with at least one co-author from Germany collected the highest total number of citations to date. Furthermore, Germany didn’t simply achieve this top rank just because it “co-authored” the most articles. In fact, their English colleagues published slightly more articles in specialist journals between 1996 and 2006, which, in turn, have been cited less frequently on average than those co-authored by researchers from Germany.
A very strong third place was achieved by Italy leaving France a considerable distance behind, in fourth place.
When taking a look at the average citation rate per article for each country, as in many previous analyses, Scandinavia steps into the limelight. The clear race leader is Finland with 14.7 citations per article in the gastroenterology and hepatology journals, followed by Sweden (13.8), Denmark (13.6) and Norway (12.5). The best non-Scandinavian country is Switzerland with 11.7 citations per article.
Extending the analysis beyond Europe, another surprise might be that European researchers clearly outran their US colleagues by number of citations and, in particular, by number of articles. As in almost all preceding analyses, however, US authors performed better by average citation rate per article.
A particularly strong result, when compared to the analyses of other life science disciplines in former Lab Times issues, was achieved by Japan, which even outperformed Europe’s number one, Germany.
However, let’s go back to the Top 30 list of Europe’s most highly cited gastroenterology and hepatology researchers. Given the country’s strong performance in the international analysis it isn’t unexpected that exactly half of the Top 30 researchers was working in Germany during 1996 and 2006. Among them is the clear-cut leader of the list, Michael P. Manns, from Hannover Medical School. It is somewhat surprising, however, that the two next best countries brought only three researchers into the list: England two and Italy one. On the other hand, six researchers from France achieved ranks among the Top 30 and three from the Netherlands (at places 3, 5 and 7).
What do the top authors and top papers (see table p. 42) finally tell us about the “hot” research topics of gastroenterology and hepatology? Well, apparently it is not colon cancer, hepatocarcinoma or another tumour disease of the digestive organs. According to our publication analysis, the five most-cited “heads” place their main research focus on hepatitis C or Morbus Crohn, an autoimmune disease of the gastrointestinal tract. The four most-cited papers also present two studies each on hepatitis C and Morbus Crohn.
That doesn’t necessarily mean that cancers of the digestive tract are of lower interest to gastroenterology and hepatology researchers. It seems likely, however, that the specialists from definite tumour research dominate those projects.
We will be checking this in a future issue, when analysing the publication output of European cancer research.
Articles appearing between 1996 and 2006 in gastroenterology and hepatology journals as listed by Thomson Scientific. Their citation numbers were recorded up until July 2008. A country’s figures are derived from articles where at least one author working in the respective European nation is included in the author’s list. Israel is included because it is a member of many European research organisations (EMBO, FEBS etc.), and also participates in the EU Research Framework Programmes.
Citations of articles published between 1996 and 2006 were recorded until May 2008 using the database Web of Science from Thomson Scientific. The “most cited papers” had correspondence addresses in Europe or Israel.
... and the World
Most Cited Authors...
|1.||Michael P. Manns, Gastroenterol. & Hepatol., Hannover Med. Sch.||15.700||668|
|2.||Thierry Poynard, Hepato-Gastroenterol., Univ. Hosp. Paris||13.738||235|
|3.||Paul J. Rutgeerts, Gastroenterol., Univ. Hosp. Leuven||13.080||286|
|4.||Markus W. Büchler, Visceral & Transplantat. Surg., Univ. Heidelberg||12.804||682|
|5.||Sander J.H. van Deventer, Exp. Med., Med. Ctr. Univ. Amsterdam||11.672||245|
|6.||Joan Rodés, Liver Unit, IDIBAPS, Univ. Hosp. Barcelona||10.643||277|
|7.||Guido N. Tytgat, Gastroenterol. & Hepatol., Univ. Amsterdam||9.782||342|
|8.||Dieter Häussinger, Gastroenterol. & Hepatol., Univ. Hosp. Düsseldorf||9.709||352|
|9.||Manfred Stolte, Pathol., Bayreuth Hosp. (Ger)||9.432||354|
|10.||Jean-Frédéric Colombel, Hepatogastroenterol., Univ. Hosp. Lille||9.377||216|
|11.||Christian Trepo, Hepato-Gastroenterol., Hosp. Hôtel-Dieu Lyon||9.305||291|
|12.||Helmut Friess, Gen. Surg., Tech. Univ. Munich||9.214||403|
|13.||Stefan Zeuzem, Internal Med., Univ. Frankfurt||9.010||241|
|14.||Giovanni Gasbarrini, Internal Med., Univ. Sacred Heart Rome||8.825||519|
|15.||Christopher J. Hawkey, Wolfson Digest. Dis. Ctr., Univ. Nottingham||8.664||167|
|16.||Jürgen Schölmerich, Internal Med., Univ. Regensburg||8.303||532|
|17.||Peter J. Meier, Clin. Pharmacol. Toxicol., Univ. Hosp. Zurich (now Basel)||8.011||154|
|18.||Roger Williams, Hepatol., Univ. Coll. London||7.918||286|
|19.||Patrick Marcellin, Hepatol., Hosp. Beaujon Clichy Univ. Paris||7.696||160|
|20.||Peter Neuhaus, Surg., Hosp. Charité Humboldt Univ. Berlin||7.511||584|
|21.||Paule Opolon, Inst. Gustave Roussy Villejuif||7.476||139|
|22.||Stefan Schreiber, Clin. Mol. Biol., Dept. Med. Univ. Kiel||7.282||207|
|23.||Peter R. Galle, Internal Med., Univ. Hosp. Mainz||7.107||216|
|24.||Guido Adler, Gastroenterol., Internal Med. Univ. Ulm||6.988||289|
|25.||Gilles Thomas, Med. Genet., Found. J. Dausset INSERM Univ. Paris||6.903||100|
|26.||Dietrich Keppler, German Canc. Res. Ctr. Heidelberg||6.644||84|
|27.||Penti Sipponen, Pathol., Univ. Hosp. Helsinki||6.627||114|
|28.||Eckhart G. Hahn, Dept Med 1, Univ Erlangen Nurnberg||6.612||457|
|29.||Hans G. Beger, Gen. Surg. Univ. Hosp. Ulm||6.414||311|
|30.||Wolfgang Stremmel, Gastroenterol. & Hepatol. Univ. Heidelberg||6.311||220|
... and Papers
|1.||Manns, MP; McHutchison, JG; Gordon, SC; ...; Albrecht, JK|
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
LANCET, 358 (9286): 958-965 SEP 22 2001
|2.||Hugot, JP; Chamaillard, M; Zouali, H; ...; Colombel, JF; Sahbatou, M; Thomas, G|
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease.
NATURE, 411 (6837): 599-603 MAY 31 2001
|3.||Poynard, T; Marcellin, P; Lee, SS; Niederau, C; ...; Zeuzem, S; Trepo, C; Albrecht, J|
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
LANCET, 352 (9138): 1426-1432 OCT 31 1998
|4.||Poynard, T; Bedossa, P; Opolon, P|
Natural history of liver fibrosis progression in patients with chronic hepatitis C.
LANCET, 349 (9055): 825-832 MAR 22 1997
|5.||Dieterich, W; Ehnis, T; Bauer, M; Donner, P; Volta, U; Riecken, EO; Schuppan, D|
Identification of tissue transglutaminase as the autoantigen of celiac disease.
NATURE MEDICINE, 3 (7): 797-801 JUL 1997
Last Changed: 31.03.2012